Polaryx Therapeutics names Will Charlton chief medical officer
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as chief medical officer to lead clinical execution for PLX-200 and the SOTERIA Phase 2 trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.